NCT03658772 - Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 20, 2018

Primary Completion Date

March 7, 2023

Study Completion Date

March 7, 2023

Conditions

Microsatellite Stable Colorectal Cancer

Interventions

DRUG

grapiprant

Cohort 1 will be treated for 1 week with oral grapiprant as a single agent, followed by 21-day combination treatment cycles of oral grapiprant in combination with IV pembrolizumab.

DRUG

grapiprant and pembrolizumab

Cohort 2 will be administered 21-day combination treatment cycles of oral grapiprant in combination with IV pembrolizumab.

Trial Locations (4)

37203

Sarah Cannon Research Institute, LLC (SCRI), Nashville

78240

New Experimental Therapeutics of San Antonio-NEXT Oncology, San Antonio

80045

University of Colorado Denver-Anschutz Medical Campus, Aurora

85054

Mayo Clinic Cancer Center - Scottsdale, Phoenix